Literature DB >> 15466404

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

Chryso Kanthou1, Olga Greco, Anna Stratford, Ian Cook, Richard Knight, Omar Benzakour, Gillian Tozer.   

Abstract

The tubulin-binding agent combretastatin A-4-phosphate (CA-4-P), rapidly disrupts the vascular network of tumors leading to secondary tumor cell death. In vitro, CA-4-P destabilizes microtubules and causes endothelial cell death. In this study we analyze the mechanisms by which CA-4-P induces the death of proliferating endothelial cells. We demonstrate that at >/=7.5 nmol/L, CA-4-P damages mitotic spindles, arrests cells at metaphase, and leads to the death of mitotic cells with characteristic G(2)/M DNA content. Mitotic arrest was associated with elevated levels of cyclin B1 protein and p34(cdc2) activity. Inhibition of p34(cdc2) activity by purvalanol A caused mitotic-arrested cells to rapidly exit mitosis, suggesting that sustained p34(cdc2) activity was responsible for metaphase arrest. Pharmacological prevention of entry into mitosis protected cells from undergoing cell death, further establishing the link between mitosis and cell death induction by CA-4-P. CA-4-P-mediated cell death shared characteristics of apoptosis but was independent of caspase activation suggesting the involvement of a non-caspase pathway(s). These data suggest that induction of apoptosis in endothelial cells by CA-4-P is associated with prolonged mitotic arrest. Therefore, by activating cell death pathways, CA-4-P, in addition to being an effective anti-vascular agent, may also interfere with regrowth of blood vessels in the tumor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466404      PMCID: PMC3118836          DOI: 10.1016/S0002-9440(10)63398-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Flow cytometry in analysis of cell cycle and apoptosis.

Authors:  Z Darzynkiewicz; E Bedner; P Smolewski
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

2.  Up-regulation of cdc2 protein during paclitaxel-induced apoptosis.

Authors:  P Chadebech; I Truchet; L Brichese; A Valette
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

Review 3.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

Review 4.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

Review 5.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

6.  Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

Authors:  G M Tozer; V E Prise; J Wilson; R J Locke; B Vojnovic; M R Stratford; M F Dennis; D J Chaplin
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.

Authors:  Y H Ling; U Consoli; C Tornos; M Andreeff; R Perez-Soler
Journal:  Int J Cancer       Date:  1998-03-16       Impact factor: 7.396

8.  The tumour microcirculation as a target in cancer therapy: a clearer perspective.

Authors:  J Denekamp
Journal:  Eur J Clin Invest       Date:  1999-09       Impact factor: 4.686

9.  The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

10.  Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Authors:  Sanaa M Nabha; Ramzi M Mohammad; Mahmoud H Dandashi; Brigitte Coupaye-Gerard; Amro Aboukameel; George R Pettit; Ayad M Al-Katib
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

View more
  16 in total

1.  Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.

Authors:  Cheng-Huang Shen; Jia-Jen Shee; Jin-Yi Wu; Yi-Wen Lin; Jiann-Der Wu; Yi-Wen Liu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells.

Authors:  Hong Zhu; Jun Zhang; Na Xue; Yongzhou Hu; Bo Yang; Qiaojun He
Journal:  Invest New Drugs       Date:  2010-03-30       Impact factor: 3.850

Review 3.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

4.  Endonuclease G mediates endothelial cell death induced by carbamylated LDL.

Authors:  Eugene O Apostolov; Debarti Ray; Wilson M Alobuia; Marina V Mikhailova; Xiaoying Wang; Alexei G Basnakian; Sudhir V Shah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-01       Impact factor: 4.733

5.  Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.

Authors:  Katharina Mahal; Bernhard Biersack; Henrike Caysa; Rainer Schobert; Thomas Mueller
Journal:  Invest New Drugs       Date:  2015-02-14       Impact factor: 3.850

6.  Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Authors:  Vinod Kumar Sanna; Manu Jaggi; Vadlapudi Kumar; Anand C Burman
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

7.  Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.

Authors:  Sonia Arora; Xin I Wang; Susan M Keenan; Christina Andaya; Qiang Zhang; Youyi Peng; William J Welsh
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

8.  Design, synthesis and biological evaluation of imidazopyridine-propenone conjugates as potent tubulin inhibitors.

Authors:  Ibrahim Bin Sayeed; V Lakshma Nayak; Mohd Adil Shareef; Neeraj Kumar Chouhan; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-03-06       Impact factor: 3.597

9.  Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2.

Authors:  George R Pettit; Peter D Quistorf; Jeremy A Fry; Delbert L Herald; Ernest Hamel; Jean-Charles Chapuis
Journal:  J Nat Prod       Date:  2009-05-22       Impact factor: 4.050

10.  New (3-(1H-benzo[d]imidazol-2-yl))/(3-(3H-imidazo[4,5-b]pyridin-2-yl))-(1H-indol-5-yl)(3,4,5-trimethoxyphenyl)methanone conjugates as tubulin polymerization inhibitors.

Authors:  Kishore Mullagiri; V Lakshma Nayak; Satish Sunkari; Geeta Sai Mani; Sravanthi Devi Guggilapu; Burri Nagaraju; Abdullah Alarifi; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-12-12       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.